Geovanne Pedro Mauro1, Pedro Pereira Neffá2, Rosangela Correa Villar3,4, Gracia Aparecida Martinez2, Heloísa de Andrade Carvalho3,5. 1. Department of Radiology and Oncology - Radiotherapy - Faculdade de Medicina da Universidade de São Paulo. Avenida Doutor Arnaldo, 155 - Cerqueira César, 01255-000 Sao Paulo - SP, Brazil. 2. Department of Hematology, Instituto do Câncer do Estado de São Paulo (ICESP) and Medical School of Sao Paulo University, Brazil. 3. Department of Radiology and Oncology, Instituto de Radiologia do Hospital das Clínicas, Medical School os Sao Paulo University, Brazil. 4. Radiotherapy Department of Boldrini Childrens Center, Campinas, São Paulo, Brazil. 5. Hospital Sírio-Libanês, São Paulo, Brazil.
Abstract
BACKGROUND: Although much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied. PATIENTS AND METHODS: Fifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT. RESULTS: Mean age at diagnosis was 57.3 years (18-80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis. CONCLUSION: BE and survival end-points were correlated. BE should be investigated in prospective trials.
BACKGROUND: Although much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied. PATIENTS AND METHODS: Fifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT. RESULTS: Mean age at diagnosis was 57.3 years (18-80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis. CONCLUSION: BE and survival end-points were correlated. BE should be investigated in prospective trials.
Authors: Noopur Raje; Evangelos Terpos; Wolfgang Willenbacher; Kazuyuki Shimizu; Ramón García-Sanz; Brian Durie; Wojciech Legieć; Marta Krejčí; Kamel Laribi; Li Zhu; Paul Cheng; Douglas Warner; G David Roodman Journal: Lancet Oncol Date: 2018-02-09 Impact factor: 41.316
Authors: Mahmut Ozsahin; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Oner Dinçbas; Christine Landmann; Bernard Castelain; Jeroen Buijsen; Jürgen Curschmann; Sidney P Kadish; Anna Kowalczyk; Yavuz Anacak; Josef Hammer; Tan D Nguyen; Gabriela Studer; Rachel Cooper; Meriç Sengöz; Luciano Scandolaro; Abderrahim Zouhair Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-17 Impact factor: 7.038
Authors: Yi Qian; Debajyoti Bhowmik; Nandita Kachru; Rohini K Hernandez; Paul Cheng; Alexander Liede Journal: Support Care Cancer Date: 2017-10-23 Impact factor: 3.603
Authors: J Caers; B Paiva; E Zamagni; X Leleu; J Bladé; S Y Kristinsson; C Touzeau; N Abildgaard; E Terpos; R Heusschen; E Ocio; M Delforge; O Sezer; M Beksac; H Ludwig; G Merlini; P Moreau; S Zweegman; M Engelhardt; L Rosiñol Journal: J Hematol Oncol Date: 2018-01-16 Impact factor: 17.388